An observational study in Retinopathy of Prematurity, sponsored by Oregon Health and Science University. Recruiting at 5 sites in United States. Open to participants aged Up to 1 Year, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-20.
Sponsored by Oregon Health and Science University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Retinopathy of Prematurity with a site in United States — 6 open to participants now, 10 under way, none of them phase 3. Retinopathy of Prematurity · United States.
Among the 51 studies in Retinopathy of Prematurity with a site in United States, this one is the 2nd largest by planned enrollment of the 15 observational ones that give a count, is one of 2 that started in 2011, is one of 15 observational ones, and was the 38th registered.
170 studies on the registry are indexed under Retinopathy of Prematurity; 28 are open to participants now.
Browse Retinopathy of Prematurity studies →6 of the 51 studies in Retinopathy of Prematurity with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 0 days–9 mo
FELIQS INC. · Sites in United States
Ages 4 days–5 days
Vanderbilt University Medical Center · Sites in United States
Ages 24 wk–34 wk
Duke University · Sites in United States
Ages up to 2 mo
Duke University · Sites in United States
Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 19 Retinopathy of Prematurity studies recruiting now, 7 (37%) set no upper age limit and 12 (63%) stop at 75 or younger; 19 take children under 18; 4 take healthy volunteers.
This study: Up to 1 Year · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 13 · Phase 3 11 · Phase 4 1
First in 1986; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,000 is above the median of 183 across 58 observational studies indexed under Retinopathy of Prematurity.
Median enrollment 114 across the 32 interventional studies, 102 across the 15 observational. Of the 35 that completed or were terminated, 14 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 51 have an industry lead sponsor. The 10 most frequent:
Oregon Health and Science University is the lead sponsor of 697 studies on the registry; 129 are open to participants now.
Of its 53 completed or terminated interventional studies of FDA-regulated products, 39 (74%) have results posted.
Oregon Health and Science University has 1 study filed under Retinopathy of Prematurity — fewer than ten, so there is no comparison to draw.
3 of the studies in Retinopathy of Prematurity with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07093255FELIQS INC.Safety, PK and PD of FLQ-101 in Premature Neonates | 2026-12-31 |
| NCT04995341Duke UniversityRetinal Microanatomy in Retinopathy of Prematurity (BabySTEPS2) | 2027-03-31 |
| NCT05558059Duke UniversityImaging Retinal Vasculature in Infant Eyes | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 51 studies in Retinopathy of Prematurity with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Retinopathy of Prematurity (ROP) is a vascular disease affecting the retinas (back of the eye) of low birth weight infants. Although it can be treated effectively if diagnosed early, it continues to be a leading cause of childhood blindness in the United States and throughout the world. The investigators feel that this study will result in specific knowledge discovery about ROP, as well as general knowledge about how image-based data and genetic data can be combined to better understand clinical disease.
Participants will be recruited from the neonatal intensive care unit (NICU) at OHSU, along with 4 collaborating institutions (William Beaumont Hospital, Stanford University, University of Illinois Chicago and University of Utah). Hospitalized infants who receive ROP screening examinations for routine care will be eligible for this study, and will be offered the opportunity to participate. Subjects who provide informed consent will have clinical data from routine care collected along with demographic characteristics, results from routine ROP screening examinations, presence of systemic disease or risk factors. Retinal photographs will be taken during these routine eye exams, using a commercially-available camera that has been FDA-cleared for taking pictures from retinas of premature infants. These retinal pictures do not contain any identifiable patient information, and are taken as routine standard of care.
The long-term goal of this research is to establish a quantitative framework for retinopathy of prematurity (ROP) care based on clinical, imaging, genetic, and informatics principles. The investigators have previously recruited and rigorously phenotyped and genotyped a large study cohort, including implementation of a novel reference standard diagnosis; and built a world-class research consortium for image, genetic, and bioinformatics analysis.
This NIH funded multi-center study began July 2011 with 8 study sites approved by their individual IRBs. Recruitment and data was conducted at the following sites: OHSU, Columbia Universtiy, Cornell College, William Beaumont Hospital, Children's Hospital LA, University of Miami, University of Illinois Chicago, Cedars Sinai Medical Center and Asociacion para Evitar la Ceguera (APEC) in Mexico City. For the competitive renewal of the grant which begins 6-01-20, the recruitment sites have been reduced to 5 which include OHSU, William Beaumont, University of Illinois Chicago, University of Utah and Stanford University.
This study will aim to develop a quantitative framework for ROP care using artificial intelligence and analytics to improve clinical disease management. The investigators will evaluate performance of an artificial intelligence system for ROP diagnosis and screening prospectively. This will include: (a) recruit a target of over 2000 eye exams including wide-angle retinal images from 375 subjects at 5 centers, (b) optimize an image quality detection algorithm the investigators have recently developed, and (c) analyze system accuracy for ROP diagnosis (plus vs. pre-plus vs. normal) and screening (using a novel quantitative vascular severity scale).
The proposed work will study infants who will receive routine ophthalmoscopic exams and have retinal images taken at each exam according to the standard of care at each institution. At least one person at each site is trained to capture wide-angle retinal images using a commercially-available camera (RetCam; Natus, Pleasanton, CA). This device is FDA-cleared for premature infants, and has been used throughout the world for 20 years with no known complications.
All participating infants will undergo retinal photography by trained study personnel for up to 3 eye exams, or more if clinically indicated and feasible. "Outborn infants," who were transferred to the study center for specialized ROP care, will have at least one set of images taken if this is clinically indicated and feasible. These coded retinal images will be read and interpreted by remote expert graders using the secure web-based system developed for this study 9 years ago at OHSU. The de-identified images will be housed indefinitely in an OHSU IRB-approved repository for possible future research studies or for other educational purposes.
Most infants recruited from the first 9 years of this study between July 2011 and May 2020 had DNA collected from blood or saliva samples. The coded genetic samples are housed in an OHSU IRB-approved repository and will be analyzed by outside collaborators for specific aim 3 of this study. Note that this current study does not involve new collection of any blood or saliva samples.
In recent years, our team has successfully developed competitive image assessment methods to infer ROP status using (i) engineered image features based on translating descriptive and visual descriptions related to expert assessment . and (ii) deep-learned features based on end-to-end training of neural networks for image analysis. To improve model explainability, the models must not only provide classification (diagnostic) labels or severity scores, but also supplementary information regarding how a model produces its decisions and what about a particular image drives the decision. To this end, it is helpful for a model to (i) visualize its training data; and (ii) illustrate which features of the input image its decision relied heavily on. Visualization can provide an overarching demonstration of how a model produces its decisions across a dataset with known clinical and demographic characteristics, which contributes to overall interpretability of the model's logic. Illustration is essential to gain trust and to facilitate validation when clinicians rely on the model to assess a particular instance for various purposes, including training or regulatory approval.
While training the AI system in previous work, the investigators excluded 5% of images that were rated by the majority of graders as "not acceptable quality". For real-world use, it will be important to balance imageability with diagnostic performance. The investigators propose to evaluate our existing dataset to determine the optimal operating point in the CNN quality algorithm that balances imageability with diagnostic performance of the i-ROP DL classifier. The investigators will continue those studies to systematically examine their impact on improving image quality and diagnostic performance - and maximize rigor and reproducibility of study design. This operating point will then be "locked", and the closed system will be used as below.
Prospective evaluation of i-ROP DL classifier: The investigators propose to calculate the weighted kappa between the RSD and the i-ROP DL system, along with sensitivity, specificity, and imageability based on the optimal operating points identified above.
Prospective evaluation of vascular severity score: In a cross sectional analysis, the investigators will test the hypothesis that the ROP vascular severity score, derived from the i-ROP DL classifier, may demonstrate high sensitivity both for detection of plus disease and for identifying treatment-requiring disease in a real-world ROP screening population.
Premature babies that are born earlier than 31 weeks gestational age or less than 1500 grams and are hospitalized at one of the 5 participating recruitment sites.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Premature infants who are at risk of retinopathy of prematurity(ROP) at participating study sites. As standard of care, babies who are born less than 31 weeks gestational age or less than 1500 grams are routinely screened for ROP. Families are approached to participate in this study where finding from babies' eye exams and associated retinal images along with demographic and other health data are collected and coded with unique identifier. No intervention is administered. The ROP exams and images obtained are done as a standard of care and would be performed even if there is no consent provided.
Other: No intervention administered.
Eye exams are standard of care and would be performed regardless of participation in this study.
Evaluate diagnostic accuracy of an AI system for ROP diagnosis
Premature babies are examined for retinopathy of prematurity (ROP), a potentially blinding diesese. As a standard of care, retinal images are taken during ROP examinations. This research group has collected a repository of images over the past 9 years and with those images, the investigators have developed an artificial intelligence (AI) system that has the ability to diagnose severe ROP with high accuracy. The primary outcome measure in continuing to recruit subjects for this study is to collect more images to improve the existing AI system and expand the ability to diagnose ROP.
Time frame: 4 years
Plan to share: Yes — All study subject data will be assigned a unique study code and recorded in a format OHSU-####, where: (a) OHSU refers to the study center that subject was recruited from (to distinguish from subjects recruited from other centers), (b) #### is a sequential number. The key to the unique study code linking the identity of the subjects will be kept in secure password protected files accessible only to authorized study personnel. De-identified data from outside sites and coded data from OHSU will be stored indefinitely in a secure IRB approved repository (7775) and may be used for future research studies. Only de-identified data will be shared with outside research collaborators.
Supporting information: Study protocol, Informed consent form
Time frame: Unknown at this time.
Access criteria: Undetermined at this time.
No publications or documents are linked to this record.
Started Jul 2011 (actual). Primary completion is estimated for May 2024, 154 months after the start.
Of 26 observational studies under Retinopathy of Prematurity, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 53. This study's planned 154 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Oregon Health and Science University →